Relevance of angiogenesis in neuroendocrine tumors

While traditional cytotoxic drugs have shown limited efficacy in neuroendocrine tumors (NETs), their biological features have been characterized and can be exploited therapeutically. Their most prominent trait is an extraordinary vascularization in low-grade NETs and an hypoxia-dependent angiogenesi...

ver descrição completa

Detalhes bibliográficos
Autores: Teulé-Vega, Àlex, Casanovas i Casanovas, Oriol
Formato: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2012
País:España
Recursos:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/171585
Acesso em linha:https://hdl.handle.net/2445/171585
Access Level:acceso abierto
Palavra-chave:Tumors
Angiogènesi
Neovascularization
id ES_99bb8b2fa0e44ad2a83c14b40a4c5b8d
oai_identifier_str oai:diposit.ub.edu:2445/171585
network_acronym_str ES
network_name_str España
repository_id_str
spelling Relevance of angiogenesis in neuroendocrine tumorsTeulé-Vega, ÀlexCasanovas i Casanovas, OriolTumorsAngiogènesiTumorsNeovascularizationWhile traditional cytotoxic drugs have shown limited efficacy in neuroendocrine tumors (NETs), their biological features have been characterized and can be exploited therapeutically. Their most prominent trait is an extraordinary vascularization in low-grade NETs and an hypoxia-dependent angiogenesis in high-grade NETs, which is associated to a significant expression of many pro-angiogenic molecules. Therefore, several antiangiogenic compounds have been tested in these malignancies and among these, sunitinib has demonstrated activity in pancreatic NET patients by dually targeting the VEGFR and PDGFR pathways. In spite of these efficacious clinical results, apparent resistance to antiangiogenic therapies has been described in NETs animal models and in clinical trials. Therefore, overcoming anti-angiogenic resistance is a crucial step in the subsequent development of antiangiogenic therapies. Several strategies have been postulated to fight resistance, but pre-clinical studies and clinical trials will investigate and address these therapeutic approaches in the coming years in order to overcome resistance anti-angiogenic therapies in NETs.Springer Science and Business Media LLC2012info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/171585Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: https://doi.org/10.1007/s11523-012-0217-xTargeted Oncology, 2012, vol. 7, issue. 2, p. 93-98https://doi.org/10.1007/s11523-012-0217-x(c) Springer Science and Business Media LLC, 2012info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1715852026-05-27T06:46:51Z
dc.title.none.fl_str_mv Relevance of angiogenesis in neuroendocrine tumors
title Relevance of angiogenesis in neuroendocrine tumors
spellingShingle Relevance of angiogenesis in neuroendocrine tumors
Teulé-Vega, Àlex
Tumors
Angiogènesi
Tumors
Neovascularization
title_short Relevance of angiogenesis in neuroendocrine tumors
title_full Relevance of angiogenesis in neuroendocrine tumors
title_fullStr Relevance of angiogenesis in neuroendocrine tumors
title_full_unstemmed Relevance of angiogenesis in neuroendocrine tumors
title_sort Relevance of angiogenesis in neuroendocrine tumors
dc.creator.none.fl_str_mv Teulé-Vega, Àlex
Casanovas i Casanovas, Oriol
author Teulé-Vega, Àlex
author_facet Teulé-Vega, Àlex
Casanovas i Casanovas, Oriol
author_role author
author2 Casanovas i Casanovas, Oriol
author2_role author
dc.subject.none.fl_str_mv Tumors
Angiogènesi
Tumors
Neovascularization
topic Tumors
Angiogènesi
Tumors
Neovascularization
description While traditional cytotoxic drugs have shown limited efficacy in neuroendocrine tumors (NETs), their biological features have been characterized and can be exploited therapeutically. Their most prominent trait is an extraordinary vascularization in low-grade NETs and an hypoxia-dependent angiogenesis in high-grade NETs, which is associated to a significant expression of many pro-angiogenic molecules. Therefore, several antiangiogenic compounds have been tested in these malignancies and among these, sunitinib has demonstrated activity in pancreatic NET patients by dually targeting the VEGFR and PDGFR pathways. In spite of these efficacious clinical results, apparent resistance to antiangiogenic therapies has been described in NETs animal models and in clinical trials. Therefore, overcoming anti-angiogenic resistance is a crucial step in the subsequent development of antiangiogenic therapies. Several strategies have been postulated to fight resistance, but pre-clinical studies and clinical trials will investigate and address these therapeutic approaches in the coming years in order to overcome resistance anti-angiogenic therapies in NETs.
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/171585
url https://hdl.handle.net/2445/171585
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1007/s11523-012-0217-x
Targeted Oncology, 2012, vol. 7, issue. 2, p. 93-98
https://doi.org/10.1007/s11523-012-0217-x
dc.rights.none.fl_str_mv (c) Springer Science and Business Media LLC, 2012
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Springer Science and Business Media LLC, 2012
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Science and Business Media LLC
publisher.none.fl_str_mv Springer Science and Business Media LLC
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414312981823488
score 15.300719

Registos relacionados